The Keys to Finding New Treatments
You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!
Key Questions
- What new preventative and acute treatments are coming soon?
- Why aren’t more people diagnosed with migraine?
- What are some common barriers to getting appropriate care, and how can we overcome them?
Interview Notes
Find more about Peter Goadsby, MD and his work here:
- Migraine Disability Assessment Score (MIDAS)
- Headache Impact Test (HIT)
Peter Goadsby, MD, PhD, FRS
Professor of Neurology and Neurologist
King's College London
Dr. Peter J. Goadsby is one of the world’s leading headache neurologists and researchers. He is a professor at King’s College London and an emeritus professor at the University of California, Los Angeles (UCLA). Dr. Goadsby is on the board of directors of the American Headache Society, and is also a trustee for The Migraine Trust.
He serves on the scientific advisory board and executive committee for the American Registry for Migraine Research (ARMR). He was one of the first to explore calcitonin gene-related peptide (CGRP), the protein known for its involvement in migraine. This discovery has been instrumental in creating the new class of medications CGRP blockers, including Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), Nurtec ODT (rimegepant), Qulipta (atogepant), and Vyepti (eptinezumab).
Purchase full access to the entire 2024 Summit to unlock:
- All expert interviews with separate audio (MP3) files & transcripts
- 30 extended, uncut interview editions with hours more expert footage
- Lifetime on-demand access with no annual fee to 2024 Summit
- Interview Summaries
- Treatment Directory & Guidelines
- And much more!
Related Talks for: Day 1 (2018) – Migraine Essentials
Aging with Migraine: Changes and Long Term Effects
Allan Purdy, MD
How Migraine Affects Your Mood: Anxiety & Depression
Dawn C. Buse, PhD
